Syria's healthcare sector requires comprehensive reconstruction across approximately half of pre-war hospital capacity. SIMA Partners provides Damascus-based research and advisory on diagnostics, dialysis, and hospital opportunities under the post-2025 framework.
Approximately half of Syria's pre-war hospitals are non-functional. The primary care network is patchy across governorates. Out-of-pocket health expenditure is approximately 45 percent of total health spending, among the highest in the eastern Mediterranean. The Ministry of Health's stated 2031 vision targets a health coverage index of 70, full facility rehabilitation, health insurance coverage of 1.6 million beneficiaries by 2028, and a reduction of out-of-pocket spending to 40 percent. The capital required to deliver any of those targets is not in the public-sector budget. Private capital is.
The healthcare opportunity in Syria is one of the more analytically straightforward theses in the reconstruction economy. Demand is structural and rising. Supply has collapsed. The post-Decree 114/2025 regulatory framework accommodates private and public-private partnership structures. The Ministry of Health is engaging international operators and sovereign healthcare funds. And unlike sectors gated entirely by the banking constraint, healthcare can absorb capital today through structures that work around current banking limitations.
The post-2025 health sector strategy in Syria addresses three structural problems. The first is facility rehabilitation: a substantial share of healthcare infrastructure was damaged or destroyed during the conflict, and the rebuild requires capital and operational expertise that the public sector cannot provide unilaterally. The second is workforce: nursing density is below WHO benchmarks for low- and middle-income countries, and specialist gaps in critical clinical areas — anaesthesia and nephrology among them — constrain the entire system. The third is the merger problem: three wartime health systems must be consolidated into a single national framework — the regime system, the opposition system, and the autonomous administration system in the northeast.
International engagement has accelerated. The World Health Organization is supporting facility assessment and prioritisation. The World Bank is engaged on public financial management for the Ministry of Health. UNDP is supporting primary care system design. Bilateral health agreements with Türkiye, Saudi Arabia, the UAE, Qatar, and Jordan are in various stages of negotiation. Multiple Gulf and European hospital operators have signalled interest in Syrian market entry. The Ministry's digital transformation programme, anchored on DHIS-II, is the architecture through which patient records, facility utilisation, and health insurance coverage will be tracked. Implementation is phased; Damascus and Aleppo are first in the rollout.
The healthcare opportunity is real and the regulatory framework is supportive. The deadlock sits in three places. The workforce gap is the most binding: a new diagnostic centre with imported MRI and CT equipment cannot operate at commercial throughput without trained radiologists, technicians, and support staff. The diaspora is a partial solution — Syrian-trained physicians in Germany, the Gulf, and North America have begun returning — but the full pipeline rebuild is a decade-horizon project. Investors entering in the next two years should plan for workforce as the gating constraint.
The reimbursement architecture is the second deadlock. Out-of-pocket payment dominates. The Ministry's target of expanding formal insurance coverage to 1.6 million beneficiaries by 2028 will create a partial reimbursement base, but most healthcare investment in 2026 and 2027 will serve the private-pay segment. Operators who design business models around that population, rather than waiting for full insurance coverage, are the ones moving now.
The third deadlock is supplier-and-equipment financing, which is acute for capital-intensive segments such as radiology and dialysis where imported equipment dominates the CAPEX profile.
Three sub-sectors are absorbing the most active healthcare capital in Syria today.
Diagnostics — radiology and clinical laboratory services — is the largest near-term opportunity. CAPEX benchmarks for a multi-modality radiology centre in Damascus or Aleppo run approximately $3.1 million; a high-throughput clinical laboratory benchmarks at approximately $792,000. Both segments serve a private-pay population that exists today, which means they can ramp to commercial revenue within twelve to eighteen months of facility opening.
Renal and dialysis services are the second active segment. CAPEX for a six-station dialysis centre benchmarks at approximately $635,000. End-stage renal disease prevalence is significant and creates substantial unmet dialysis demand. The existing dialysis network operates at capacity.
Hospital reconstruction is the third segment, with longer timelines and larger ticket sizes. Multiple Gulf and European hospital operators are in early-stage discussions on greenfield and brownfield hospital projects in Damascus, Aleppo, and Homs. Deal sizes range from approximately $20 million to $200 million, with structures including direct ownership, public-private partnerships under Decree 114/2025, and management contracts on rehabilitated public facilities.
The Syrian Investment Authority is the entry point for major healthcare capital deployment. The Ministry of Health is the line ministry for licensing, regulatory approval, and clinical governance. Decree 114/2025 governs both wholly-owned private healthcare operations and public-private partnerships on existing public facilities.
The framework provides for foreign majority ownership, fiscal incentives during construction and early operations, and currency-conversion mechanisms for legitimate operating cash flow. Specific licensing varies by sub-sector: diagnostic centres face shorter and lighter regulatory paths than full hospitals, dialysis units have a streamlined approval process tied to clinical accreditation, and pharmacy and pharmaceutical distribution operate under separate frameworks.
The healthcare workforce regulatory framework is the most operationally important consideration for new investors. Foreign-trained physicians require Syrian Medical Association accreditation; Syrian-trained physicians returning from abroad face streamlined recognition processes that have been further accelerated under post-2025 reforms.
Can foreign investors own Syrian healthcare facilities?
Yes. Decree 114/2025 and the Syrian investment framework allow foreign majority ownership in healthcare facilities, including diagnostic centres, hospitals, dialysis units, and clinical laboratories. Specific licensing is required from the Ministry of Health and the Syrian Investment Authority.
What healthcare segments offer the strongest near-term returns?
Diagnostics — radiology and clinical laboratory — and renal/dialysis services offer the strongest near-term commercial profiles, with shorter development timelines, manageable CAPEX, and immediate private-pay demand. Greenfield hospitals offer larger ticket sizes but longer development cycles.
Who is the regulatory authority for Syrian healthcare?
The Ministry of Health is the line ministry for licensing, regulation, clinical governance, and pharmaceutical oversight. The Syrian Investment Authority handles investment-side approvals. The Syrian Medical Association handles physician credentialing.
How does the workforce gap affect new healthcare investment?
Workforce is the single most operationally important factor for new healthcare investors. New facilities should plan for staffing as the gating constraint on commercial ramp-up. Diaspora returnee programmes, partnerships with regional medical schools, and structured training programmes are the three primary workforce-development paths.
What is the role of medical tourism in Syria's healthcare strategy?
Pre-war Syria was a regional centre for medical tourism, particularly from Iraq, Lebanon, and Jordan, drawn by the country's medical workforce and price competitiveness. The new healthcare strategy includes a medical tourism component, but realisation is dependent on facility rebuild, workforce restoration, and the broader stabilisation of patient-mobility regulations across the region.
What is DHIS-II?
DHIS-II (District Health Information System version 2) is the digital health information platform anchoring the Ministry of Health's digital transformation programme. It provides the architecture through which patient records, facility utilisation, and health insurance coverage will be tracked.
Primary research on Syria's healthcare sector, pharmaceutical markets, and reconstruction opportunities.
Tell us about your healthcare mandate. From hospital infrastructure assessments to pharmaceutical market intelligence, we scope engagements around the decision you need to make.
Start a Conversation